Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
1996 pubmed

Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6.

Dickson. S L SL; Doutrelant-Viltart. O O; Dyball. R E RE; Leng. G G

Key Findings

  • Around 70‑80% of the arcuate nucleus neurons activated by GHRP‑6 are neurosecretory cells that project beyond the blood‑brain barrier.
  • Very few of the activated neurons are dopaminergic (TH‑positive) or beta‑endorphin‑producing cells (<7% and ~0.3% respectively).
  • This suggests GHRP‑6’s primary action in the hypothalamus is on hormone‑releasing neurons rather than on dopamine or opioid pathways.

Practical Outcomes

  • For biohackers, the data reinforces that GHRP‑6 works by stimulating hypothalamic hormone‑secreting neurons, supporting its use as a growth‑hormone secretagogue. It doesn’t change dosing or protocol, but it confirms the peptide’s mechanism isn’t tied to dopamine or beta‑endorphin systems, which may allay concerns about those pathways.

Summary

The study shows that when you give GHRP‑6 to rats, it turns on a large share (about 70‑80%) of hypothalamic neurons that send signals out of the brain to release hormones. These activated cells are not the dopamine‑producing (TH) or beta‑endorphin cells, meaning GHRP‑6 mainly stimulates other hormone‑releasing neurons, likely the ones that trigger growth hormone release.

Abstract

Previously, we demonstrated that the synthetic hexapeptide GH-releasing peptide (GHRP-6) activates a subpopulation of arcuate neurones, as reflected by increased electrical activation and by the detection of Fos protein in cell nuclei. Here we set out to determine (1) what proportion of the cells activated by GHRP-6 are neurosecretory neurones and (2) whether the cells activated by GHRP-6 contain tyrosine hydroxylase (TH; a marker of dopaminergic cells in this region) or beta-endorphin. In the first study, adult male rats were injected i.v. with the retrograde tracer, Fluorogold, to detect cells which project outside the blood-brain barrier (and are therefore likely to be neurosecretory neurones). Three days later the conscious rats were injected i.v. with 50 micrograms GHRP-6 and the brains processed for the immunocytochemical detection of Fos protein. Between 68% and 82% of the arcuate neurones expressing Fos protein following GHRP-6 injection were retrogradely labelled with Fluorogold. In the second study, conscious male rats, bearing a chronically implanted jugular catheter, were killed 90 min following an i.v. injection of 50 micrograms GHRP-6 and the brains were processed for the double immunocytochemical detection of Fos protein and either TH or beta-endorphin. Less than 7% (mean +/- S.E.M. = 6.7 +/- 2.6% nuclei/section per rat) of the arcuate neurones expressing Fos protein following GHRP-6 injection were TH-containing cells. Of 143 beta-endorphin-containing arcuate cells detected only four cells were identified as containing Fos protein. Thus, the majority of arcuate neurones activated by GHRP-6 (1) project outside the blood-brain barrier (and are therefore likely to be neuro-secretory neurones) and (2) were not identified as TH- or beta-endorphin-containing cells.

Study Information

Provider

pubmed

Year

1996

DOI

10.1677/joe.0.1510323